Centauri Therapeutics Receives An Additional $5.1 M From Carb-x To Progress Abx-01 Lead Compound To First In Human Clinical Trials

Centauri Therapeutics Limited ('Centauri'), an immunotherapy institution pinch a unsocial and proprietary level exertion applicable crossed a wide scope of therapeutic indications, announced coming that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an further $5.1 M successful backing for nan improvement of their lead compound. The costs will lend to nan advancement of nan lead campaigner successful Centauri's ABX-01 programme into first successful quality objective studies, and this latest backing brings CARB-X's full support from 2019 to day to $12.3 M.

Centauri announced nan action of its first objective campaigner successful nan ABX-01 programme successful March 2025. The campaigner is simply a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. Based connected nan Company's proprietary Alphamer platform, it is designed to target superior Gram-negative bacterial infections successful nan lung, expanding therapeutic options for nan astir susceptible patients. It employs a dual system of action, combining immunotherapeutic effects done complement fixation and phagocytosis pinch intrinsic antibacterial properties, wrong a azygous molecule. Early efficacy studies person demonstrated nan compound's activity against Gram-negative bacteria.

"The unwavering technological and financial support from CARB-X has provided stableness to Centauri arsenic a company, expanded knowing of our Alphamer platform, and enabled america to advancement nan ABX-01 programme from discovery, done early development, and is now providing a soft and continuous way towards First successful Human objective studies," said Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics. "We are thankful for CARB-X and their continued engagement and confidence, which has allowed america to move a measurement person to delivering a overmuch needed therapeutic for serious, drug-resistant Gram-negative infections, moreover successful nan astir clinically susceptible patients."

We person been proud to support Centauri, opening pinch answering cardinal questions connected nan attack and continuing pinch nan supplier find that has led to nan lead plus of ABX-01 and its progression towards building a dossier to support its advancement into first successful quality objective trials."

Dr. Erin Duffy, Chief of Research and Development, CARB-X

CARB-X's backing for this task is provided successful portion pinch national costs from nan U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; nether statement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany's Federal Ministry of Research, Technology and Space (BMFTR). The contented of this property merchandise is solely nan work of nan authors and does not needfully correspond nan charismatic views of CARB-X aliases immoderate of its funders.